Topix Appoints Brenda Wu as New President & CEO
Topix Pharmaceuticals, the leading independent provider of premium, custom and branded skincare, today announced the appointment of Brenda Wu as President and CEO. Brenda adds these responsibilities to her existing role as President and CEO of Topix-owned DERMA E, one of the fasting growing clean, green and accessible skincare brands. Wu will lead Topix, which is backed by New Mountain Capital, a growth-oriented investment firm that currently manages more than $20 billion in assets, into its next phase of growth. New Mountain Capital invested in Topix to provide equity capital to execute a growth strategy, including both organic and acquisition-led growth.
In her new role, Wu will lead all aspects of revenue and profit growth, including R&D, new product development, sales & marketing, operations and strategic corporate development. Under Wu’s leadership, Topix will continue to build awareness of its world-class skincare products by investing in sales, marketing and digital capabilities as well as furthering the Company’s leadership in R&D, physician commitment and turnkey service.
Wu joins Topix after more than a decade of success at L’Oréal, where she led trusted brands such as SkinCeuticals, Giorgio Armani Beauty, Lancôme and Kiehl’s. At L’Oréal, Wu served as U.S. General Manager of SkinCeuticals and under Wu’s leadership, SkinCeuticals became the #1 professional skincare brand in the U.S. Prior to L’Oréal, Wu led teams in retail merchandising at Banana Republic, digital marketing at AOL Time Warner and strategy consulting at Bain & Company. Wu is a graduate of Harvard College, holds a M.B.A. from Harvard Business School and has also attended Harvard Law School and the Christine Valmy Esthetics school.
“Brenda is a proven leader with an exceptional track-record of delivering results through dedication to her teams, ongoing innovation and partnership with customers,” added Andre Moura, Managing Director at New Mountain Capital and Chairman of the Board of Directors of Topix. “We couldn’t be more excited to see Brenda lead the Topix business into the future as we continue to support increased investments in Topix to better serve our customers.”
“I am thrilled and honored to join Topix as President and CEO,” commented Wu. “Topix was built on a foundation of the most advanced research and development and clinically proven formulas that are tested and customized for dermatologists. I look forward to furthering our mission of developing cutting-edge technologies, building our physician partners’ unique brands and helping physicians build their own businesses. I am excited to be working with the Topix team to take the business to new heights.”
Topix is the independent leader in skincare with a differentiated portfolio of clinically-proven products, custom and consumer brands sold across high-growth channels. Topix was founded in 1981 and built its reputation in the physician market where it is the largest provider of premium, customized and branded skincare products, partnering with over 3,000 physicians in the U.S. Topix’s portfolio of products are clinically-validated and manufactured in the Company’s state-of-the-art, FDA-registered facility in New York. For more information on Topix, please visit: http://www.topixpharm.com/.
About New Mountain Capital
New Mountain Capital is a New York based investment firm that emphasizes business building and non-cyclical growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over $20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit: www.newmountaincapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005103/en/